ASCO
May 31, 2019
ASCO Annual Meeting 2019, May 31-June 4, Chicago, IL, USA
Year
2019
Target
PIM/FLT3
Assets in this page
Download assets
- pdf file
"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"
Download